<?xml version='1.0' encoding='utf-8'?>
<document id="24885714"><sentence text="Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy."><entity charOffset="22-34" id="DDI-PubMed.24885714.s1.e0" text="lumefantrine" /></sentence><sentence text="Malaria and HIV infections are both highly prevalent in sub-Saharan Africa, with HIV-infected patients being at higher risks of acquiring malaria" /><sentence text=" The majority of antiretroviral (ART) and anti-malarial drugs are metabolized by the CYP450 system, creating a chance of drug-drug interaction upon co-administration" /><sentence text=" Limited data are available on the effectiveness of the artemether-lumefantrine combination (AL) when co-administered with non-nucleoside reverse transcriptase inhibitors (NNRTIs)"><entity charOffset="67-79" id="DDI-PubMed.24885714.s4.e0" text="lumefantrine" /></sentence><sentence text=" The aim of this study was to compare anti-malarial treatment responses between HIV-1 infected patients on either nevirapine- or efavirenz-based treatment and those not yet on ART (control-arm) with uncomplicated falciparum malaria, treated with AL"><entity charOffset="129-138" id="DDI-PubMed.24885714.s5.e0" text="efavirenz" /></sentence><sentence text="" /><sentence text="This was a prospective, non-randomized, open-label study conducted in Bagamoyo district, with three arms of HIV-infected adults: efavirenz-based treatment arm (EFV-arm) n = 66, nevirapine-based treatment arm (NVP-arm) n = 128, and control-arm n = 75, with uncomplicated malaria"><entity charOffset="129-138" id="DDI-PubMed.24885714.s7.e0" text="efavirenz" /><entity charOffset="177-187" id="DDI-PubMed.24885714.s7.e1" text="nevirapine" /><pair ddi="false" e1="DDI-PubMed.24885714.s7.e0" e2="DDI-PubMed.24885714.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24885714.s7.e0" e2="DDI-PubMed.24885714.s7.e1" /></sentence><sentence text=" All patients were treated with AL and followed up for 28 days" /><sentence text=" The primary outcome measure was an adequate clinical and parasitological response (ACPR) after treatment with AL by day 28" /><sentence text="" /><sentence text="Day 28 ACPR was 97" /><sentence text="6%, 82" /><sentence text="5% and 94" /><sentence text="5% for the NVP-arm, EFV-arm and control-arm, respectively" /><sentence text=" No early treatment or late parasitological failure was reported" /><sentence text=" The cumulative risk of recurrent parasitaemia was &gt;19-fold higher in the EFV-arm than in the control-arm (Hazard ratio [HR], 19" /><sentence text="11 [95% confidence interval {CI}, 10" /><sentence text="5-34" /><sentence text="5]; P &lt; 0" /><sentence text="01)" /><sentence text=" The cumulative risk of recurrent parasitaemia in the NVP-arm was not significantly higher than in the control-arm ([HR], 2" /><sentence text="44 [95% {CI}, 0" /><sentence text="79-7" /><sentence text="6]; P = 0" /><sentence text="53)" /><sentence text=" The median (IQR) day 7 plasma concentrations of lumefantrine for the three arms were: 1,125 ng/m (638"><entity charOffset="49-61" id="DDI-PubMed.24885714.s26.e0" text="lumefantrine" /></sentence><sentence text="8-1913), 300" /><sentence text="4 ng/ml (220" /><sentence text="8-343" /><sentence text="1) and 970 ng/ml (562" /><sentence text="1-1729) for the NVP-arm, the EFV-arm and the control-arm, respectively (P &lt; 0" /><sentence text="001)" /><sentence text=" In all three arms, the reported adverse events were mostly mild" /><sentence text="" /><sentence text="After 28 days of follow-up, AL was statistically safe and effective in the treatment of uncomplicated malaria in the NVP-arm" /><sentence text=" The results of this study also provide an indication of the possible impact of EFV on the performance of AL and the likelihood of it affecting uncomplicated falciparum malaria treatment outcome" /><sentence text="" /></document>